New Baker interview, page-51

Clyde,

What I want and what I believe needs to happen is for some on here to stop blinding following Hopper, to look at the facts and tell it as it really is, just to say Hopper will fix it because of what he has done elsewhere doesnt cut the mustard.

Hopper needs to know that shareholders are far from happy, yes he has stated he know he needs to win back shareholder support but his action dont live up to that.

Now I am no brain child but it's a clear as ones nose that what Suda needs to be concentrating on is Teva deal and seeing why it's over 12 months late, the data used was all based on the FDA application so why no approval, the Australia Zolpimist application is also based on the same data, this doesnt look good.

The second issues is the Stride deal, unless there has been a big I crease in the development spending on SUD001H in the last quarter it appears very little is being done to get this product ready for a in man trial, which once done triggers a milestone payment.

Get either of these imo it would Do more to attract investment than consolidation or interviews.

If they get one product onto shelves in their territories just think what that would Do to the market.

We all need to call Hopper out